stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Revenue growth
Organon & Co.'s revenue growth over the twelve months to 30 September 2026 was −3.21%, down 0.3 percentage points from fiscal 2025 (−2.92%). Over the past ten years it has ranged from −20.5% (fiscal 2019) to 7.39% (fiscal 2017); the current reading is higher than 56% of that period. That is below the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −2.92% | (5.16) |
| FY2024 | 2.24% | 0.80 |
| FY2023 | 1.44% | 3.50 |
| FY2022 | −2.06% | 1.43 |
| FY2021 | −3.49% | 12.52 |
| FY2020 | −16.0% | 4.45 |
| FY2019 | −20.5% | (13.57) |
| FY2018 | −6.89% | (14.28) |
| FY2017 | 7.39% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −1.75% | 0.51 |
| Jun 2026 | −2.26% | 1.24 |
| Mar 2026 | −3.50% | 1.84 |
| Dec 2025 | −5.34% | (6.60) |
| 23 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 11.1% |
| GRFS Grifols, S.A. compare | 10.9% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| BIIB Biogen Inc. compare | 2.30% |
| PFE Pfizer Inc. compare | 1.34% |
| OGN Organon & Co. | −3.21% |
| AMRN Amarin Corporation PLC compare | −22.3% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement